Literature DB >> 19824822

MyD88-dependent silencing of transgene expression during the innate and adaptive immune response to helper-dependent adenovirus.

Masataka Suzuki1, Vincenzo Cerullo, Terry K Bertin, Racel Cela, Christian Clarke, Margaretha Guenther, Nicola Brunetti-Pierri, Brendan Lee.   

Abstract

Activation of the host innate immune response after systemic administration of adenoviral vectors constitutes a principal impediment to successful clinical gene replacement therapies. Although helper-dependent adenoviruses (HDAds) lack all viral functional genes, systemic administration of a high dose of HDAd still elicits a potent innate immune response in host animals. Toll-like receptors (TLRs) are innate receptors that sense microbial products and trigger the maturation of antigen-presenting cells and cytokine production via MyD88-dependent signaling (except TLR3). Here we show that mice lacking MyD88 exhibit a dramatic reduction in proinflammatory cytokines after intravenous injection of a high dose of HDAd, and show significantly reduced induction of the adaptive immune response when compared with wild-type and TLR2-deficient mice. Importantly, MyD88(-/-) mice also show significantly higher and longer sustained transgene expression than do wild-type mice. Chromatin immunoprecipitation studies using wild-type and MyD88-deficient primary mouse embryonic fibroblasts showed significant MyD88-dependent transcriptional silencing of the HDAd-encoded transgenes. Our results demonstrate that MyD88 signaling, activated by systemic delivery of HDAd, initiates an innate immune response that suppresses transgene expression at the transcriptional level before initiation of the adaptive immune response.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19824822      PMCID: PMC2865218          DOI: 10.1089/hum.2009.155

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  45 in total

Review 1.  Type 1 interferons and the virus-host relationship: a lesson in détente .

Authors:  Adolfo García-Sastre; Christine A Biron
Journal:  Science       Date:  2006-05-12       Impact factor: 47.728

2.  Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector.

Authors:  Scott E Hensley; Ann S Cun; Wynetta Giles-Davis; Yan Li; Zhiquan Xiang; Marcio O Lasaro; Bryan R G Williams; Robert H Silverman; Hildegund C J Ertl
Journal:  Mol Ther       Date:  2007-02       Impact factor: 11.454

Review 3.  Pathogen recognition and innate immunity.

Authors:  Shizuo Akira; Satoshi Uematsu; Osamu Takeuchi
Journal:  Cell       Date:  2006-02-24       Impact factor: 41.582

4.  Adenovirus efficiently transduces plasmacytoid dendritic cells resulting in TLR9-dependent maturation and IFN-alpha production.

Authors:  Etiena Basner-Tschakarjan; Evelyn Gaffal; Meredith O'Keeffe; Damia Tormo; Andreas Limmer; Hermann Wagner; Hubertus Hochrein; Thomas Tüting
Journal:  J Gene Med       Date:  2006-11       Impact factor: 4.565

5.  Helper-dependent adenoviral gene therapy mediates long-term correction of the clotting defect in the canine hemophilia A model.

Authors:  W M McCORMACK; M P Seiler; T K Bertin; K Ubhayakar; D J Palmer; P Ng; T C Nichols; B Lee
Journal:  J Thromb Haemost       Date:  2006-06       Impact factor: 5.824

6.  Preferential activation of Toll-like receptor nine by CD46-utilizing adenoviruses.

Authors:  Milena Iacobelli-Martinez; Glen R Nemerow
Journal:  J Virol       Date:  2006-11-15       Impact factor: 5.103

7.  Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production.

Authors:  Naoya Koizumi; Tomoko Yamaguchi; Kenji Kawabata; Fuminori Sakurai; Tomomi Sasaki; Yoshiteru Watanabe; Takao Hayakawa; Hiroyuki Mizuguchi
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

8.  Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors.

Authors:  Vincenzo Cerullo; Michael P Seiler; Viraj Mane; Nicola Brunetti-Pierri; Christian Clarke; Terry K Bertin; John R Rodgers; Brendan Lee
Journal:  Mol Ther       Date:  2007-02       Impact factor: 11.454

9.  Improved hepatic transduction, reduced systemic vector dissemination, and long-term transgene expression by delivering helper-dependent adenoviral vectors into the surgically isolated liver of nonhuman primates.

Authors:  Nicola Brunetti-Pierri; Thomas Ng; David A Iannitti; Donna J Palmer; Arthur L Beaudet; Milton J Finegold; K Dee Carey; William G Cioffi; Philip Ng
Journal:  Hum Gene Ther       Date:  2006-04       Impact factor: 5.695

10.  Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response.

Authors:  Catherine S Manno; Glenn F Pierce; Valder R Arruda; Bertil Glader; Margaret Ragni; John J Rasko; John Rasko; Margareth C Ozelo; Keith Hoots; Philip Blatt; Barbara Konkle; Michael Dake; Robin Kaye; Mahmood Razavi; Albert Zajko; James Zehnder; Pradip K Rustagi; Hiroyuki Nakai; Amy Chew; Debra Leonard; J Fraser Wright; Ruth R Lessard; Jürg M Sommer; Michael Tigges; Denise Sabatino; Alvin Luk; Haiyan Jiang; Federico Mingozzi; Linda Couto; Hildegund C Ertl; Katherine A High; Mark A Kay
Journal:  Nat Med       Date:  2006-02-12       Impact factor: 53.440

View more
  21 in total

Review 1.  Innate immunity to adenovirus: lessons from mice.

Authors:  Svetlana Atasheva; Jia Yao; Dmitry M Shayakhmetov
Journal:  FEBS Lett       Date:  2019-12-08       Impact factor: 4.124

2.  The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver.

Authors:  Ashley T Martino; Masataka Suzuki; David M Markusic; Irene Zolotukhin; Renee C Ryals; Babak Moghimi; Hildegund C J Ertl; Daniel A Muruve; Brendan Lee; Roland W Herzog
Journal:  Blood       Date:  2011-04-07       Impact factor: 22.113

3.  NOD2 signaling contributes to the innate immune response against helper-dependent adenovirus vectors independently of MyD88 in vivo.

Authors:  Masataka Suzuki; Racel Cela; Terry K Bertin; Gautam Sule; Vincenzo Cerullo; John R Rodgers; Brendan Lee
Journal:  Hum Gene Ther       Date:  2011-07-08       Impact factor: 5.695

4.  Kinome-level screening identifies inhibition of polo-like kinase-1 (PLK1) as a target for enhancing non-viral transgene expression.

Authors:  Matthew D Christensen; Jacob J Elmer; Seron Eaton; Laura Gonzalez-Malerva; Joshua LaBaer; Kaushal Rege
Journal:  J Control Release       Date:  2015-02-11       Impact factor: 9.776

5.  An oncolytic adenovirus enhanced for toll-like receptor 9 stimulation increases antitumor immune responses and tumor clearance.

Authors:  Vincenzo Cerullo; Iulia Diaconu; Valentina Romano; Mari Hirvinen; Matteo Ugolini; Sophie Escutenaire; Sirkka-Liisa Holm; Anja Kipar; Anna Kanerva; Akseli Hemminki
Journal:  Mol Ther       Date:  2012-07-24       Impact factor: 11.454

6.  Helper-dependent adenoviral vector achieves prolonged, stable expression of interleukin-10 in rabbit carotid arteries but does not limit early atherogenesis.

Authors:  Liang Du; Nagadhara Dronadula; Shinji Tanaka; David A Dichek
Journal:  Hum Gene Ther       Date:  2011-04-11       Impact factor: 5.695

7.  Differential type I interferon-dependent transgene silencing of helper-dependent adenoviral vs. adeno-associated viral vectors in vivo.

Authors:  Masataka Suzuki; Terry K Bertin; Geoffrey L Rogers; Racel G Cela; Irene Zolotukhin; Donna J Palmer; Philip Ng; Roland W Herzog; Brendan Lee
Journal:  Mol Ther       Date:  2013-01-15       Impact factor: 11.454

8.  Helper-Dependent Adenoviral Vectors.

Authors:  Amanda Rosewell; Francesco Vetrini; Philip Ng
Journal:  J Genet Syndr Gene Ther       Date:  2011-10-29

9.  The human adenovirus type 5 E1B 55 kDa protein obstructs inhibition of viral replication by type I interferon in normal human cells.

Authors:  Jasdave S Chahal; Ji Qi; S J Flint
Journal:  PLoS Pathog       Date:  2012-08-09       Impact factor: 6.823

Review 10.  The role of chromatin in adenoviral vector function.

Authors:  Carmen M Wong; Emily R McFall; Joseph K Burns; Robin J Parks
Journal:  Viruses       Date:  2013-06-14       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.